skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 68  for All Library Resources

Results 1 2 3 4 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Material Type:
Article
Add to My Research

Ofatumumab versus Teriflunomide in Multiple Sclerosis

The New England journal of medicine, 2020-08, Vol.383 (6), p.546-557 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1917246 ;PMID: 32757523

Full text available

2
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Material Type:
Article
Add to My Research

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

The Lancet (British edition), 2018-03, Vol.391 (10127), p.1263-1273 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 31, 2018 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)30475-6 ;PMID: 29576505

Full text available

3
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Material Type:
Article
Add to My Research

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Lancet neurology, 2018-05, Vol.17 (5), p.405-415 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited May 2018 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1474-4422 ;ISSN: 1474-4465 ;EISSN: 1474-4465 ;DOI: 10.1016/S1474-4422(18)30069-3 ;PMID: 29545067

Full text available

4
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
Material Type:
Article
Add to My Research

Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke

The New England journal of medicine, 2013-03, Vol.368 (12), p.1092-1100 [Peer Reviewed Journal]

Copyright © 2013 Massachusetts Medical Society. All rights reserved. ;2014 INIST-CNRS ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1301440 ;PMID: 23514286 ;CODEN: NEJMAG

Full text available

5
Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
Material Type:
Article
Add to My Research

Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice

Translational stroke research, 2016-12, Vol.7 (6), p.535-547 [Peer Reviewed Journal]

The Author(s) 2016 ;ISSN: 1868-4483 ;EISSN: 1868-601X ;DOI: 10.1007/s12975-016-0496-0

Digital Resources/Online E-Resources

6
Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics
Material Type:
Article
Add to My Research

Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics

Neuroscience bulletin, 2015-12, Vol.31 (6), p.745-754 [Peer Reviewed Journal]

Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2015 ;ISSN: 1673-7067 ;EISSN: 1995-8218 ;DOI: 10.1007/s12264-015-1560-6 ;PMID: 26480875

Full text available

7
Control of microglial neurotoxicity by the fractalkine receptor
Material Type:
Article
Add to My Research

Control of microglial neurotoxicity by the fractalkine receptor

Nature neuroscience, 2006-07, Vol.9 (7), p.917-924 [Peer Reviewed Journal]

COPYRIGHT 2006 Nature Publishing Group ;Copyright Nature Publishing Group Jul 2006 ;ISSN: 1097-6256 ;EISSN: 1546-1726 ;DOI: 10.1038/nn1715 ;PMID: 16732273 ;CODEN: NANEFN

Full text available

8
Isolation of murine microglial cells for RNA analysis or flow cytometry
Material Type:
Article
Add to My Research

Isolation of murine microglial cells for RNA analysis or flow cytometry

Nature protocols, 2006-11, Vol.1 (4), p.1947-1951 [Peer Reviewed Journal]

COPYRIGHT 2006 Nature Publishing Group ;Copyright Nature Publishing Group Nov 2006 ;ISSN: 1754-2189 ;EISSN: 1750-2799 ;DOI: 10.1038/nprot.2006.327 ;PMID: 17487181

Full text available

9
Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients
Material Type:
Article
Add to My Research

Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients

Annals of neurology, 2007-07, Vol.62 (1), p.34-39 [Peer Reviewed Journal]

Copyright © 2007 American Neurological Association ;2007 INIST-CNRS ;ISSN: 0364-5134 ;EISSN: 1531-8249 ;DOI: 10.1002/ana.21085 ;PMID: 17328067 ;CODEN: ANNED3

Full text available

10
Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation
Material Type:
Article
Add to My Research

Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation

Immunological reviews, 2000-10, Vol.177 (1), p.52-67 [Peer Reviewed Journal]

ISSN: 0105-2896 ;EISSN: 1600-065X ;DOI: 10.1034/j.1600-065X.2000.17709.x ;PMID: 11138785

Full text available

11
Water quality monitoring device and monitoring method for drainage of sewage treatment plant
Material Type:
Patent
Add to My Research

Water quality monitoring device and monitoring method for drainage of sewage treatment plant

Digital Resources/Online E-Resources

12
Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod
Material Type:
Article
Add to My Research

Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod

Neurology, 2015-09, Vol.85 (11), p.1001-1003 [Peer Reviewed Journal]

2015 American Academy of Neurology ;ISSN: 0028-3878 ;EISSN: 1526-632X ;DOI: 10.1212/WNL.0000000000001929 ;PMID: 26291283

Full text available

13
Transgenic expression of CCL2 in the central nervous system prevents experimental autoimmune encephalomyelitis
Material Type:
Article
Add to My Research

Transgenic expression of CCL2 in the central nervous system prevents experimental autoimmune encephalomyelitis

Journal of leukocyte biology, 2005-02, Vol.77 (2), p.229-237 [Peer Reviewed Journal]

2005 Society for Leukocyte Biology ;ISSN: 0741-5400 ;EISSN: 1938-3673 ;DOI: 10.1189/jlb.0804465 ;PMID: 15539456

Full text available

14
Pertussis Toxin-Induced Reversible Encephalopathy Dependent on Monocyte Chemoattractant Protein-1 Overexpression in Mice
Material Type:
Article
Add to My Research

Pertussis Toxin-Induced Reversible Encephalopathy Dependent on Monocyte Chemoattractant Protein-1 Overexpression in Mice

The Journal of neuroscience, 2002-12, Vol.22 (24), p.10633-10642 [Peer Reviewed Journal]

Copyright © 2002 Society for Neuroscience 2002 ;ISSN: 0270-6474 ;EISSN: 1529-2401 ;DOI: 10.1523/jneurosci.22-24-10633.2002 ;PMID: 12486156

Full text available

15
Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis
Material Type:
Article
Add to My Research

Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis

Central nervous system agents in medicinal chemistry, 2009-03, Vol.9 (1), p.20-31 [Peer Reviewed Journal]

ISSN: 1871-5249 ;DOI: 10.2174/187152409787601923

Full text available

16
Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs (P7-3.011)
Material Type:
Article
Add to My Research

Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs (P7-3.011)

Neurology, 2023-04, Vol.100 (17_supplement_2) [Peer Reviewed Journal]

ISSN: 0028-3878 ;EISSN: 1526-632X ;DOI: 10.1212/WNL.0000000000203085

Full text available

17
Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial
Material Type:
Article
Add to My Research

Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial

Circulation (New York, N.Y.), 2015-09, Vol.132 (12), p.1104-1112 [Peer Reviewed Journal]

2015 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2015 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.115.016371 ;PMID: 26202811

Full text available

18
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
Material Type:
Article
Add to My Research

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

Lancet neurology, 2014-07, Vol.13 (7), p.657-665 [Peer Reviewed Journal]

Copyright © 2014 Elsevier Ltd. All rights reserved. ;EISSN: 1474-4465 ;DOI: 10.1016/S1474-4422(14)70068-7 ;PMID: 24794721

Full text available

19
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
Material Type:
Article
Add to My Research

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

The New England journal of medicine, 2022-08, Vol.387 (8), p.704-714 [Peer Reviewed Journal]

Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;COPYRIGHT 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2201904

Full text available

20
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
Material Type:
Article
Add to My Research

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Lancet neurology, 2021-09, Vol.20 (9), p.729-738 [Peer Reviewed Journal]

2021 Elsevier Ltd ;2021. Elsevier Ltd ;ISSN: 1474-4422 ;EISSN: 1474-4465 ;DOI: 10.1016/S1474-4422(21)00237-4 ;PMID: 34418400

Full text available

Results 1 - 20 of 68  for All Library Resources

Results 1 2 3 4 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (54)

Refine My Results

Creation Date 

From To
  1. Before 2001  (11)
  2. 2001 To 2005  (9)
  3. 2006 To 2010  (9)
  4. 2011 To 2016  (17)
  5. After 2016  (23)
  6. More options open sub menu

Language 

  1. Chinese  (11)
  2. Japanese  (8)
  3. French  (2)
  4. More options open sub menu

Searching Remote Databases, Please Wait